Raymond James Financial
EPRX

Raymond James Financial’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Raymond James Financial’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$366K Sell
50,560
-2,412
-5% -$19.4K ﹤0.01% 4554
2025
Q4 		$400K Buy
52,972
+19,599
+59% +$121K ﹤0.01% 4410
2025
Q3 		$197K Buy
33,373
+21,161
+173% +$115K ﹤0.01% 4626
2025
Q2 		$70.3K Buy
12,212
+1,079
+10% +$4.14K ﹤0.01% 5037
2025
Q1 		$36.5K Sell
11,133
-480
-4% -$1.66K ﹤0.01% 4667
2024
Q4 		$36.8K Buy
+11,613
New +$34.4K ﹤0.01% 4651

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Raymond James Financial's EPRX Position: Q1 2026 in Review

Raymond James Financial reduced its Eupraxia Pharmaceuticals (EPRX) stake by 4.6% in Q1 2026, selling an estimated $19.4K and leaving 50,560 shares worth $366K. The position accounts for ﹤0.01% of the portfolio, ranked #4554.

Raymond James Financial first reported a position in EPRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $400K in Q4 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Raymond James Financial held 50,560 shares of Eupraxia Pharmaceuticals worth $366K as of Q1 2026.
  • Raymond James Financial sold 2,412 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $19.4K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4554 holding.
  • Raymond James Financial first reported a position in Eupraxia Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Eupraxia Pharmaceuticals position peaked at $400K in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.